ZA200701176B - Vaccines against aids comprising CMV/R-nucleic acid constructs - Google Patents
Vaccines against aids comprising CMV/R-nucleic acid constructsInfo
- Publication number
- ZA200701176B ZA200701176B ZA200701176A ZA200701176A ZA200701176B ZA 200701176 B ZA200701176 B ZA 200701176B ZA 200701176 A ZA200701176 A ZA 200701176A ZA 200701176 A ZA200701176 A ZA 200701176A ZA 200701176 B ZA200701176 B ZA 200701176B
- Authority
- ZA
- South Africa
- Prior art keywords
- nucleic acid
- acid constructs
- cmv
- immune response
- vaccines against
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
- 230000028993 immune response Effects 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16271—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16371—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58837804P | 2004-07-16 | 2004-07-16 | |
PCT/US2004/030284 WO2005034992A2 (en) | 2003-09-15 | 2004-09-15 | Hiv vaccines based on env of multiple clades of hif |
PCT/US2005/012291 WO2005110492A2 (en) | 2004-04-12 | 2005-04-12 | Method of using adenoviral vectors to induce an immune response |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200701176B true ZA200701176B (en) | 2008-09-25 |
Family
ID=44369798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200701176A ZA200701176B (en) | 2004-07-16 | 2007-02-09 | Vaccines against aids comprising CMV/R-nucleic acid constructs |
Country Status (10)
Country | Link |
---|---|
US (2) | US20090214588A1 (xx) |
EP (2) | EP2397490B1 (xx) |
JP (1) | JP4772045B2 (xx) |
CN (1) | CN101277971A (xx) |
AT (1) | ATE527281T1 (xx) |
AU (1) | AU2005274948B2 (xx) |
BR (1) | BRPI0513390A (xx) |
CA (1) | CA2573702C (xx) |
WO (1) | WO2006020071A2 (xx) |
ZA (1) | ZA200701176B (xx) |
Families Citing this family (141)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2281252B1 (es) * | 2005-07-27 | 2009-02-16 | Consejo Superior De Investigaciones Cientificas | Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida. |
PT3335728T (pt) | 2008-10-10 | 2020-02-19 | Childrens Medical Center | Vacina de trímero de envelope para hiv-1 bioquimicamente estabilizada |
GB0823497D0 (en) | 2008-12-24 | 2009-01-28 | Isis Innovation | Immunogenic composition and use thereof |
WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
US20110177115A1 (en) * | 2009-10-02 | 2011-07-21 | Tomas Hanke | Vaccination regimen |
US20110200573A1 (en) * | 2010-02-04 | 2011-08-18 | Derya Unutmaz | Methods of inhibiting retrovirus replication and infectivity |
US9186370B2 (en) | 2010-03-19 | 2015-11-17 | University Of South Alabama | Methods and compositions for the treatment of cancer |
WO2012021730A2 (en) * | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
WO2012135696A2 (en) | 2011-04-01 | 2012-10-04 | University Of South Alabama | Methods and compositions for the diagnosis, classification, and treatment of cancer |
WO2013103401A1 (en) | 2012-01-06 | 2013-07-11 | University Of South Alabama | Methods and compositions for the treatment of cancer |
WO2014093701A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
MX2015007550A (es) | 2012-12-12 | 2017-02-02 | Broad Inst Inc | Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas. |
PT2898075E (pt) | 2012-12-12 | 2016-06-16 | Harvard College | Manipulação e otimização de sistemas, métodos e composições de enzima melhorados para manipulação de sequências |
US20140186843A1 (en) | 2012-12-12 | 2014-07-03 | Massachusetts Institute Of Technology | Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
SG11201505229XA (en) | 2013-01-07 | 2015-08-28 | Beth Israel Hospital | Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same |
EP3011029B1 (en) | 2013-06-17 | 2019-12-11 | The Broad Institute, Inc. | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
AU2014281028B2 (en) | 2013-06-17 | 2020-09-10 | Massachusetts Institute Of Technology | Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy |
CA2915845A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells |
JP6702858B2 (ja) | 2013-06-17 | 2020-06-03 | ザ・ブロード・インスティテュート・インコーポレイテッド | ウイルス成分を使用して障害および疾患をターゲティングするためのCRISPR−Cas系および組成物の送達、使用および治療上の適用 |
EP4245853A3 (en) | 2013-06-17 | 2023-10-18 | The Broad Institute, Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
WO2015009946A1 (en) * | 2013-07-17 | 2015-01-22 | Emory University | Method of increasing immune response to hiv antigens |
US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
WO2015089419A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
WO2015089473A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation |
CN111206032A (zh) | 2013-12-12 | 2020-05-29 | 布罗德研究所有限公司 | 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用 |
SG10201804973TA (en) | 2013-12-12 | 2018-07-30 | Broad Inst Inc | Compositions and Methods of Use of Crispr-Cas Systems in Nucleotide Repeat Disorders |
KR20160089530A (ko) | 2013-12-12 | 2016-07-27 | 더 브로드 인스티튜트, 인코퍼레이티드 | Hbv 및 바이러스 질병 및 질환을 위한 crisprcas 시스템 및 조성물의 전달,용도 및 치료적 적용 |
EP3080271B1 (en) | 2013-12-12 | 2020-02-12 | The Broad Institute, Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
KR20160101073A (ko) | 2013-12-20 | 2016-08-24 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
WO2016028682A1 (en) | 2014-08-17 | 2016-02-25 | The Broad Institute Inc. | Genome editing using cas9 nickases |
WO2016049163A2 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder |
WO2016049024A2 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo |
WO2016049251A1 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes |
WO2016049258A2 (en) | 2014-09-25 | 2016-03-31 | The Broad Institute Inc. | Functional screening with optimized functional crispr-cas systems |
ES2865150T3 (es) | 2014-09-26 | 2021-10-15 | Beth Israel Deaconess Medical Ct Inc | Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana |
EP3212788A2 (en) | 2014-10-27 | 2017-09-06 | The Broad Institute, Inc. | Compositions, methods and use of synthetic lethal screening |
WO2016094867A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Protected guide rnas (pgrnas) |
WO2016094872A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Dead guides for crispr transcription factors |
WO2016094880A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs) |
WO2016094874A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Escorted and functionalized guides for crispr-cas systems |
WO2016100975A1 (en) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Molecular biomarkers for cancer immunotherapy |
WO2016100974A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing |
WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
WO2016106236A1 (en) | 2014-12-23 | 2016-06-30 | The Broad Institute Inc. | Rna-targeting system |
AU2015369725A1 (en) | 2014-12-24 | 2017-06-29 | Massachusetts Institute Of Technology | CRISPR having or associated with destabilization domains |
CN116196401A (zh) | 2015-05-20 | 2023-06-02 | 博德研究所 | 共有的新抗原 |
EP3822291A1 (en) | 2015-06-10 | 2021-05-19 | The Broad Institute Inc. | Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia |
WO2016205745A2 (en) * | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Cell sorting |
EP3666895A1 (en) | 2015-06-18 | 2020-06-17 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
AU2016279062A1 (en) | 2015-06-18 | 2019-03-28 | Omar O. Abudayyeh | Novel CRISPR enzymes and systems |
CN108290933A (zh) | 2015-06-18 | 2018-07-17 | 布罗德研究所有限公司 | 降低脱靶效应的crispr酶突变 |
US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
EP3337908A4 (en) | 2015-08-18 | 2019-01-23 | The Broad Institute, Inc. | METHOD AND COMPOSITIONS FOR CHANGING THE FUNCTION AND STRUCTURE OF CHROMATIN GRINDING AND / OR DOMAINS |
WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
KR20180133374A (ko) | 2015-10-22 | 2018-12-14 | 더 브로드 인스티튜트, 인코퍼레이티드 | 타입 vi-b crispr 효소 및 시스템 |
EP3368687B1 (en) | 2015-10-27 | 2021-09-29 | The Broad Institute, Inc. | Compositions and methods for targeting cancer-specific sequence variations |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
JP6510149B2 (ja) * | 2015-12-15 | 2019-05-08 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
WO2017106657A1 (en) | 2015-12-18 | 2017-06-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
AU2017254477A1 (en) | 2016-04-18 | 2018-11-01 | Jennifer G. ABELIN | Improved HLA epitope prediction |
KR102670601B1 (ko) | 2016-04-19 | 2024-05-29 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신규한 crispr 효소 및 시스템 |
US11286478B2 (en) | 2016-04-19 | 2022-03-29 | The Broad Institute, Inc. | Cpf1 complexes with reduced indel activity |
AU2017257274B2 (en) | 2016-04-19 | 2023-07-13 | Massachusetts Institute Of Technology | Novel CRISPR enzymes and systems |
RU2018144877A (ru) * | 2016-06-03 | 2020-07-09 | Темпл Юниверсити - Оф Де Коммонвелт Систем Оф Хаер Эдьюкейшн | Регуляция HIV-1 по механизму отрицательной обратной связи с помощью стратегии редактирования генов |
KR102389489B1 (ko) | 2016-06-16 | 2022-04-22 | 얀센 백신스 앤드 프리벤션 비.브이. | Hiv 백신 제형 |
JP7267013B2 (ja) | 2016-06-17 | 2023-05-01 | ザ・ブロード・インスティテュート・インコーポレイテッド | Vi型crisprオルソログ及び系 |
WO2018005873A1 (en) | 2016-06-29 | 2018-01-04 | The Broad Institute Inc. | Crispr-cas systems having destabilization domain |
WO2018035387A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
CN110114461A (zh) | 2016-08-17 | 2019-08-09 | 博德研究所 | 新型crispr酶和系统 |
CA3035759A1 (en) | 2016-09-02 | 2018-03-08 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
US20190262399A1 (en) | 2016-09-07 | 2019-08-29 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses |
BR112019004593A2 (pt) | 2016-09-15 | 2019-07-02 | Janssen Vaccines & Prevention Bv | mutações da proteína do envelope do hiv estabilizando o trímero |
WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
CA3056236A1 (en) | 2017-03-15 | 2018-09-20 | The Broad Institute, Inc. | Novel cas13b orthologues crispr enzymes and systems |
WO2018191388A1 (en) | 2017-04-12 | 2018-10-18 | The Broad Institute, Inc. | Novel type vi crispr orthologs and systems |
WO2018191750A2 (en) | 2017-04-14 | 2018-10-18 | The Broad Institute Inc. | Novel delivery of large payloads |
US11591601B2 (en) | 2017-05-05 | 2023-02-28 | The Broad Institute, Inc. | Methods for identification and modification of lncRNA associated with target genotypes and phenotypes |
US20210278416A1 (en) | 2017-05-09 | 2021-09-09 | The Broad Institute, Inc. | Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases |
MA49397A (fr) | 2017-06-15 | 2020-04-22 | Bavarian Nordic As | Vecteurs à poxvirus codant pour des antigènes du vih, et leurs procédés d'utilisation |
WO2019005884A1 (en) | 2017-06-26 | 2019-01-03 | The Broad Institute, Inc. | CRISPR / CAS-ADENINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED NUCLEIC ACID EDITION |
US11168322B2 (en) | 2017-06-30 | 2021-11-09 | Arbor Biotechnologies, Inc. | CRISPR RNA targeting enzymes and systems and uses thereof |
SG11202000112XA (en) | 2017-07-19 | 2020-02-27 | Janssen Vaccines & Prevention Bv | Trimer stabilizing hiv envelope protein mutations |
AU2018338318B2 (en) | 2017-09-21 | 2022-12-22 | Massachusetts Institute Of Technology | Systems, methods, and compositions for targeted nucleic acid editing |
US20200255828A1 (en) | 2017-10-04 | 2020-08-13 | The Broad Institute, Inc. | Methods and compositions for altering function and structure of chromatin loops and/or domains |
US11547614B2 (en) | 2017-10-31 | 2023-01-10 | The Broad Institute, Inc. | Methods and compositions for studying cell evolution |
US20200291395A1 (en) | 2017-11-02 | 2020-09-17 | Arbor Biotechnologies, Inc. | Novel crispr-associated transposon systems and components |
EP3710039A4 (en) | 2017-11-13 | 2021-08-04 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY TARGETING THE CLEC2D-KLRB1 PATH |
WO2019178428A1 (en) | 2018-03-14 | 2019-09-19 | Arbor Biotechnologies, Inc. | Novel crispr dna and rna targeting enzymes and systems |
DE202019005567U1 (de) | 2018-03-14 | 2021-02-16 | Arbor Biotechnologies, Inc. | Neue CRISPR-DNA-Targeting-Enzyme und -Systeme |
US10968257B2 (en) | 2018-04-03 | 2021-04-06 | The Broad Institute, Inc. | Target recognition motifs and uses thereof |
AU2019266326A1 (en) | 2018-05-11 | 2020-11-26 | Beam Therapeutics Inc. | Methods of editing single nucleotide polymorphism using programmable base editor systems |
US20210198664A1 (en) | 2018-05-16 | 2021-07-01 | Arbor Biotechnologies, Inc. | Novel crispr-associated systems and components |
WO2020018142A1 (en) | 2018-07-16 | 2020-01-23 | Arbor Biotechnologies, Inc. | Novel crispr dna targeting enzymes and systems |
WO2020033601A1 (en) | 2018-08-07 | 2020-02-13 | The Broad Institute, Inc. | Novel cas12b enzymes and systems |
US20210317429A1 (en) | 2018-08-20 | 2021-10-14 | The Broad Institute, Inc. | Methods and compositions for optochemical control of crispr-cas9 |
US20210382068A1 (en) | 2018-10-02 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
WO2020131862A1 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Crispr-associated transposase systems and methods of use thereof |
WO2020127990A1 (en) | 2018-12-20 | 2020-06-25 | Biomedrex Ab | System for production of crispr-based pharmaceutical compositions |
EA202192233A1 (ru) | 2019-02-12 | 2021-11-11 | Университа' Дельи Студи Ди Тренто | МОЛЕКУЛЫ ГИДОВОЙ РНК Cas12a И ИХ ПРИМЕНЕНИЕ |
US20220119787A1 (en) | 2019-02-20 | 2022-04-21 | Biomedrex Ab | Virus therapy |
WO2020186237A1 (en) | 2019-03-13 | 2020-09-17 | The Broad Institute, Inc. | Microglial progenitors for regeneration of functional microglia in the central nervous system and therapeutics uses thereof |
EP3938379A4 (en) * | 2019-03-15 | 2023-02-22 | ModernaTX, Inc. | HIV RNA VACCINE |
US20220177863A1 (en) | 2019-03-18 | 2022-06-09 | The Broad Institute, Inc. | Type vii crispr proteins and systems |
US20220249701A1 (en) | 2019-05-14 | 2022-08-11 | The Broad Institute, Inc. | Compositions and methods for targeting multinucleated cells |
WO2020236967A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Random crispr-cas deletion mutant |
CN114423869A (zh) | 2019-07-19 | 2022-04-29 | 旗舰先锋创新Vi有限责任公司 | 重组酶组合物和使用方法 |
WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
WO2021050512A1 (en) | 2019-09-09 | 2021-03-18 | Beam Therapeutics Inc. | Novel crispr enzymes, methods, systems and uses thereof |
CN114729384A (zh) | 2019-09-12 | 2022-07-08 | 博德研究所 | 工程化腺相关病毒衣壳 |
WO2021113494A1 (en) | 2019-12-03 | 2021-06-10 | Beam Therapeutics Inc. | Synthetic guide rna, compositions, methods, and uses thereof |
WO2021152181A1 (en) | 2020-01-30 | 2021-08-05 | Biomedrex Ab | Virus therapy |
CN116249774A (zh) | 2020-05-26 | 2023-06-09 | 迪奥尼斯治疗公司 | 核酸人工微型蛋白质组文库 |
WO2022188039A1 (en) | 2021-03-09 | 2022-09-15 | Huigene Therapeutics Co., Ltd. | Engineered crispr/cas13 system and uses thereof |
WO2022068912A1 (en) | 2020-09-30 | 2022-04-07 | Huigene Therapeutics Co., Ltd. | Engineered crispr/cas13 system and uses thereof |
CN115427561B (zh) | 2021-03-09 | 2024-06-04 | 辉大(上海)生物科技有限公司 | 工程化CRISPR/Cas13系统及其用途 |
CN117529555A (zh) | 2021-03-23 | 2024-02-06 | 比姆医疗股份有限公司 | 新颖crispr酶、方法、系统及其用途 |
WO2022221699A1 (en) | 2021-04-16 | 2022-10-20 | Beam Therapeutics, Inc. | Genetic modification of hepatocytes |
EP4349979A1 (en) | 2021-05-27 | 2024-04-10 | Institute Of Zoology, Chinese Academy Of Sciences | Engineered cas12i nuclease, effector protein and use thereof |
WO2022256578A2 (en) | 2021-06-02 | 2022-12-08 | Beam Therapeutics Inc. | Circular guide rnas for crispr/cas editing systems |
WO2023004367A2 (en) | 2021-07-20 | 2023-01-26 | The Broad Institute, Inc. | Engineered targeting compositions for endothelial cells of the central nervous system vasculature and methods of use thereof |
KR20240037299A (ko) | 2021-07-23 | 2024-03-21 | 빔 테라퓨틱스, 인크. | Crispr/cas 편집 시스템용 가이드 rna |
IL311225A (en) | 2021-09-08 | 2024-05-01 | Flagship Pioneering Innovations Vi Llc | Methods and compositions for genome modulation |
IL312452A (en) | 2021-11-01 | 2024-06-01 | Tome Biosciences Inc | A transformant has a single structure for the simultaneous transfer of a gene editing mechanism and a nucleic acid cargo |
WO2023093862A1 (en) | 2021-11-26 | 2023-06-01 | Epigenic Therapeutics Inc. | Method of modulating pcsk9 and uses thereof |
CA3240917A1 (en) | 2021-12-17 | 2023-06-22 | Bernd ZETSCHE | Crispr enzymes, methzods, systems and uses thereof |
WO2023122764A1 (en) | 2021-12-22 | 2023-06-29 | Tome Biosciences, Inc. | Co-delivery of a gene editor construct and a donor template |
WO2023196772A1 (en) | 2022-04-04 | 2023-10-12 | Beam Therapeutics Inc. | Novel rna base editing compositions, systems, methods and uses thereof |
WO2023205744A1 (en) | 2022-04-20 | 2023-10-26 | Tome Biosciences, Inc. | Programmable gene insertion compositions |
WO2023215831A1 (en) | 2022-05-04 | 2023-11-09 | Tome Biosciences, Inc. | Guide rna compositions for programmable gene insertion |
WO2023225564A1 (en) | 2022-05-18 | 2023-11-23 | The Broad Institute, Inc. | Engineered viral capsids with increased stability and methods of use thereof |
WO2023225670A2 (en) | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
WO2024015892A1 (en) | 2022-07-13 | 2024-01-18 | The Broad Institute, Inc. | Hla-ii immunopeptidome methods and systems for antigen discovery |
WO2024016003A2 (en) | 2022-07-14 | 2024-01-18 | The Broad Institute, Inc. | Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor |
WO2024020587A2 (en) | 2022-07-22 | 2024-01-25 | Tome Biosciences, Inc. | Pleiopluripotent stem cell programmable gene insertion |
WO2024059791A1 (en) | 2022-09-16 | 2024-03-21 | Beam Therapeutics Inc. | Large serine recombinases, systems and uses thereof |
WO2024138194A1 (en) | 2022-12-22 | 2024-06-27 | Tome Biosciences, Inc. | Platforms, compositions, and methods for in vivo programmable gene insertion |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US5100792A (en) | 1984-11-13 | 1992-03-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues |
FR2573436B1 (fr) | 1984-11-20 | 1989-02-17 | Pasteur Institut | Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins |
US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
KR100372934B1 (ko) | 1990-09-25 | 2003-12-24 | 캔탑 파마슈티칼스 리서취 리미티드 | 형질 상보성 세포주에 의해 생성된 바이러스 결손 백신 |
US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
AU696336B2 (en) | 1993-03-19 | 1998-09-10 | Cantab Pharmaceuticals Research Limited | Defective mutant non-retroviral virus (e.g. HSV) as vaccine |
FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
HU216871B (hu) | 1993-07-13 | 1999-09-28 | Rhone-Poulenc Rorer S.A. | Defektív adenovírusvektorok és génterápiai alkalmazásuk |
US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
FR2714830B1 (fr) | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
FR2727679B1 (fr) | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
WO1996039178A1 (en) | 1995-06-05 | 1996-12-12 | The Wistar Institute Of Anatomy And Biology | A replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
US5741492A (en) * | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
US6900010B2 (en) * | 1999-01-25 | 2005-05-31 | Musc Foundation For Research Development | Compositions and methods for detecting human immunodeficiency virus |
WO2001047955A2 (en) * | 1999-12-23 | 2001-07-05 | Medical Research Council | Improvements in or relating to immune responses to hiv |
US8623379B2 (en) * | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
EP1311686A2 (en) * | 2000-08-14 | 2003-05-21 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization |
US6733993B2 (en) * | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
AU2002252199B2 (en) * | 2001-03-08 | 2008-01-03 | Emory University | MVA expressing modified HIV envelope, GAG, and POL genes |
EP1411770A4 (en) * | 2001-07-05 | 2006-05-10 | Chiron Corp | POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE |
EP1504112A4 (en) * | 2001-10-01 | 2006-02-08 | Us Health | DEVELOPMENT OF A VACCINE FOR THE PREVENTION OF INFECTIONS WITH THE FILOVIRUS IN PRIMATES |
US20030153065A1 (en) | 2002-01-14 | 2003-08-14 | Genvec, Inc. | Composition and method for maintaining non-enveloped viral vectors |
WO2005034992A2 (en) * | 2003-09-15 | 2005-04-21 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv vaccines based on env of multiple clades of hif |
-
2005
- 2005-07-15 AU AU2005274948A patent/AU2005274948B2/en not_active Ceased
- 2005-07-15 CA CA2573702A patent/CA2573702C/en not_active Expired - Fee Related
- 2005-07-15 US US11/632,522 patent/US20090214588A1/en not_active Abandoned
- 2005-07-15 EP EP10182793.9A patent/EP2397490B1/en not_active Not-in-force
- 2005-07-15 WO PCT/US2005/025219 patent/WO2006020071A2/en active Application Filing
- 2005-07-15 EP EP05791578A patent/EP1784416B1/en not_active Not-in-force
- 2005-07-15 JP JP2007521694A patent/JP4772045B2/ja not_active Expired - Fee Related
- 2005-07-15 BR BRPI0513390-4A patent/BRPI0513390A/pt not_active IP Right Cessation
- 2005-07-15 AT AT05791578T patent/ATE527281T1/de not_active IP Right Cessation
- 2005-07-15 CN CNA2005800312074A patent/CN101277971A/zh active Pending
-
2007
- 2007-02-09 ZA ZA200701176A patent/ZA200701176B/xx unknown
-
2011
- 2011-01-20 US US13/010,141 patent/US8454972B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2008508866A (ja) | 2008-03-27 |
CN101277971A (zh) | 2008-10-01 |
EP2397490B1 (en) | 2013-09-04 |
AU2005274948A1 (en) | 2006-02-23 |
JP4772045B2 (ja) | 2011-09-14 |
WO2006020071A3 (en) | 2006-05-18 |
CA2573702C (en) | 2013-10-15 |
US8454972B2 (en) | 2013-06-04 |
AU2005274948B2 (en) | 2011-09-22 |
CA2573702A1 (en) | 2006-02-23 |
EP2397490A1 (en) | 2011-12-21 |
US20090214588A1 (en) | 2009-08-27 |
US20110200636A1 (en) | 2011-08-18 |
WO2006020071A2 (en) | 2006-02-23 |
ATE527281T1 (de) | 2011-10-15 |
BRPI0513390A (pt) | 2008-05-06 |
EP1784416B1 (en) | 2011-10-05 |
EP1784416A2 (en) | 2007-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200701176B (en) | Vaccines against aids comprising CMV/R-nucleic acid constructs | |
WO2007024941A3 (en) | Polyvalent vaccine | |
EA200701128A1 (ru) | Рекомбинантные штаммы bcg, обладающие повышенной способностью к высвобождению из эндосомы | |
WO2010019262A3 (en) | Polyvalent vaccine | |
MX2008009929A (es) | Vacuna a base de levadura para inducir una respuesta inmune. | |
WO2006113214A3 (en) | Vaccine against pandemic strains of influenza viruses | |
AU2002254901A1 (en) | Influenza vaccine formulations for intradermal delivery | |
WO2012177924A3 (en) | Influenza virus mutants and uses therefor | |
WO2003072719A3 (en) | Metapneumovirus strains and their use in vaccine formulations and as vector for expression of antigenic sequences | |
WO2006063053A3 (en) | Methods of producing influenza vaccine compositions | |
EP4043031A3 (en) | Zika viral antigen constructs | |
WO2004075829A3 (en) | Adjuvanted influenza vaccine | |
WO2008039171A3 (en) | Inactivating pathogens with hydrogen peroxide for vaccine production | |
WO2006038908A3 (en) | Ancestral and cot viral sequences, proteins and immunogenic compositions | |
GB2386072A (en) | Novel vaccine | |
WO2011106607A3 (en) | Subunit vaccines for herpes viruses and methods of use | |
WO2010001409A3 (en) | Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same | |
WO2010022740A3 (en) | Hiv-1 envelope polypeptides for hiv vaccine | |
AU2017261706A1 (en) | Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process | |
WO2011106100A3 (en) | Method of inducing the production of protective anti-hiv-1 antibodies | |
WO2014150822A3 (en) | Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use | |
WO2003066094A3 (en) | Hepatitis b vaccines | |
CY1112575T1 (el) | Βελτιωμενα αδρανοποιημενα εμβολια fcv | |
WO2008060385A3 (en) | Li-key enhanced vaccine potency | |
WO2007046839A3 (en) | New live virus vaccines |